{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:53:47Z","timestamp":1791132827277,"version":"4.1.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2006,6,2]],"date-time":"2006-06-02T00:00:00Z","timestamp":1149206400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00109-006-0066-0","type":"journal-article","created":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T18:15:53Z","timestamp":1149185753000},"page":"635-646","source":"Crossref","is-referenced-by-count":83,"title":["Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein"],"prefix":"10.1007","volume":"84","author":[{"given":"Masahiro","family":"Waza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Minamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Doyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,6,2]]},"reference":[{"key":"66_CR1","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nrg1690","volume":"6","author":"NA Prospero Di","year":"2005","unstructured":"Di Prospero NA, Fischbeck KH (2005) Therapeutics development for triplet repeat expansion diseases. Nat Rev Genet 6:756\u2013765","journal-title":"Nat Rev Genet"},{"key":"66_CR2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR La Spada","year":"1991","unstructured":"La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77\u201379","journal-title":"Nature"},{"issue":"Pt 1","key":"66_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/brain\/112.1.209","volume":"112","author":"G Sobue","year":"1989","unstructured":"Sobue G, Hashizume Y, Mukai E, Hirayama M, Mitsuma T, Takahashi A (1989) X-linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain 112(Pt 1):209\u2013232","journal-title":"Brain"},{"key":"66_CR4","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/hmg\/5.9.1253","volume":"5","author":"F Tanaka","year":"1996","unstructured":"Tanaka F, Doyu M, Ito Y, Matsumoto M, Mitsuma T, Abe K, Aoki M, Itoyama Y, Fischbeck KH, Sobue G (1996) Founder effect in spinal and bulbar muscular atrophy (SBMA). Hum Mol Genet 5:1253\u20131257","journal-title":"Hum Mol Genet"},{"key":"66_CR5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/ana.410320517","volume":"32","author":"M Doyu","year":"1992","unstructured":"Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, Takahashi A (1992) Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol 32:707\u2013710","journal-title":"Ann Neurol"},{"key":"66_CR6","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/brain\/awh381","volume":"128","author":"H Adachi","year":"2005","unstructured":"Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, Nakagomi Y, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Yoshida M, Hashizume Y, Sobue G (2005) Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128:659\u2013670","journal-title":"Brain"},{"key":"66_CR7","doi-asserted-by":"crossref","first-page":"28697","DOI":"10.1074\/jbc.271.45.28697","volume":"271","author":"Y Fang","year":"1996","unstructured":"Fang Y, Fliss AE, Robins DM, Caplan AJ (1996) Hsp90 regulates androgen receptor hormone binding affinity in vivo. J Biol Chem 271:28697\u201328702","journal-title":"J Biol Chem"},{"key":"66_CR","doi-asserted-by":"crossref","first-page":"11824","DOI":"10.1021\/bi0259150","volume":"41","author":"V Georget","year":"2002","unstructured":"Georget V, Terouanne B, Nicolas JC, Sultan C (2002) Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824\u201311831","journal-title":"Biochemistry"},{"key":"66_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2004.03.001","volume":"25","author":"A Poletti","year":"2004","unstructured":"Poletti A (2004) The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol 25:1\u201326","journal-title":"Front Neuroendocrinol"},{"key":"66_CR10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/153537020322800201","volume":"228","author":"WB Pratt","year":"2003","unstructured":"Pratt WB, Toft DO (2003) Regulation of signaling protein function and trafficking by the hsp90\/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228:111\u2013133","journal-title":"Exp Biol Med (Maywood)"},{"key":"66_CR11","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1471-4914(02)02316-X","volume":"8","author":"L Neckers","year":"2002","unstructured":"Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55\u2013S61","journal-title":"Trends Mol Med"},{"key":"66_CR12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1379\/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2","volume":"7","author":"DK Vanaja","year":"2002","unstructured":"Vanaja DK, Mitchell SH, Toft DO, Young CY (2002) Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7:55\u201364","journal-title":"Cell Stress Chaperones"},{"key":"66_CR13","first-page":"986","volume":"8","author":"DB Solit","year":"2002","unstructured":"Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986\u2013993","journal-title":"Clin Cancer Res"},{"key":"66_CR14","first-page":"962","volume":"8","author":"L Neckers","year":"2002","unstructured":"Neckers L (2002) Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res 8:962\u2013966","journal-title":"Clin Cancer Res"},{"key":"66_CR15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/nm1298","volume":"11","author":"M Waza","year":"2005","unstructured":"Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, Tanaka F, Inukai A, Doyu M, Sobue G (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 11:1088\u20131095","journal-title":"Nat Med"},{"key":"66_CR16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.7164\/antibiotics.23.442","volume":"23","author":"CMP DeBoer","year":"1970","unstructured":"DeBoer CMP, Wnuk RJ, Peterson DH (1970) Geldanamycin, a new antibiotic. J Antibiot (Tokyo) 23:442\u2013447","journal-title":"J Antibiot (Tokyo)"},{"key":"66_CR17","first-page":"1721","volume":"52","author":"L Whitesell","year":"1992","unstructured":"Whitesell L, Shifrin SD, Schwab G, Neckers LM (1992) Benzoquinonoid ansamycins possess selective tumoricidal activity unrelated to src kinase inhibition. Cancer Res 52:1721\u20131728","journal-title":"Cancer Res"},{"key":"66_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1023\/A:1006382320697","volume":"17","author":"L Neckers","year":"1999","unstructured":"Neckers L, Schulte TW, Mimnaugh E (1999) Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 17:361\u2013373","journal-title":"Invest New Drugs"},{"key":"66_CR19","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/BF00689048","volume":"36","author":"JG Supko","year":"1995","unstructured":"Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305\u2013315","journal-title":"Cancer Chemother Pharmacol"},{"key":"66_CR20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002800050817","volume":"42","author":"TW Schulte","year":"1998","unstructured":"Schulte TW, Neckers LM (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 42:273\u2013279","journal-title":"Cancer Chemother Pharmacol"},{"key":"66_CR21","first-page":"308","volume":"38","author":"J Page","year":"1997","unstructured":"Page J, Heath J, Fulton R, Yalkowsky E, Tabibi E, Tomaszewski J, Smith A, Rodman L (1997) Comparison of geldanamycin (NSC-122750) and 17-allylaminogeldanamycin (NSC-330507D) toxicity in rats. Proc Am Assoc Cancer Res 38:308","journal-title":"Proc Am Assoc Cancer Res"},{"key":"66_CR22","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2005.09.119","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C (2005) Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078\u20131087","journal-title":"J Clin Oncol"},{"key":"66_CR23","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1200\/JCO.2005.00.612","volume":"23","author":"U Banerji","year":"2005","unstructured":"Banerji U, O\u2019Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23:4152\u20144161","journal-title":"J Clin Oncol"},{"key":"66_CR24","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2005.12.085","volume":"23","author":"JL Grem","year":"2005","unstructured":"Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH (2005) Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885\u20131893","journal-title":"J Clin Oncol"},{"key":"66_CR25","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1158\/1078-0432.CCR-04-2322","volume":"11","author":"RK Ramanathan","year":"2005","unstructured":"Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ (2005) Phase I pharmacokinetic\u2013pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res 11:3385\u20133391","journal-title":"Clin Cancer Res"},{"key":"66_CR26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3816\/CGC.2005.n.024","volume":"4","author":"EI Heath","year":"2005","unstructured":"Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P (2005) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer 4:138\u2013141","journal-title":"Clin Prostate Cancer"},{"key":"66_CR27","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1021\/jm050355z","volume":"48","author":"BW Dymock","year":"2005","unstructured":"Dymock BW, Barril X, Brough PA, Cansfield JE, Massey A, McDonald E, Hubbard RE, Surgenor A, Roughley SD, Webb P, Workman P, Wright L, Drysdale MJ (2005) Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 48:4212\u20134215","journal-title":"J Med Chem"},{"key":"66_CR28","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1096\/fj.05-5343fje","volume":"20","author":"CA Dickey","year":"2006","unstructured":"Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, Burrows F, Eckman C, Hutton M, Petrucelli L (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser\/Thr sites but not KXGS (MARK) sites. FASEB J 20:753\u2013755","journal-title":"FASEB J"},{"key":"66_CR29","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1016\/j.bmcl.2006.02.063","volume":"16","author":"C Avila","year":"2006","unstructured":"Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, Blagg BS (2006) High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett 16:3005\u20133008","journal-title":"Bioorg Med Chem Let"},{"key":"66_CR30","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1128\/MCB.6.6.2198","volume":"6","author":"Y Uehara","year":"1986","unstructured":"Uehara Y, Hori M, Takeuchi T, Umezawa H (1986) Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 6:2198\u20132206","journal-title":"Mol Cell Biol"},{"key":"66_CR31","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","volume":"91","author":"L Whitesell","year":"1994","unstructured":"Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90\u2013pp60v\u2013src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 91:8324\u20138328","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0092-8674(00)80314-1","volume":"90","author":"C Prodromou","year":"1997","unstructured":"Prodromou C, Roe SM, O\u2019Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP\/ADP-binding site in the Hsp90 molecular chaperone. Cell 90:65\u201375","journal-title":"Cell"},{"key":"66_CR33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","volume":"425","author":"A Kamal","year":"2003","unstructured":"Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407\u2013410","journal-title":"Nature"},{"key":"66_CR34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/425357a","volume":"425","author":"L Neckers","year":"2003","unstructured":"Neckers L, Lee YS (2003) Cancer: the rules of attraction. Nature 425:357\u2013359","journal-title":"Nature"},{"key":"66_CR35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","volume":"35","author":"M Katsuno","year":"2002","unstructured":"Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, Sang C, Kobayashi Y, Doyu M, Sobue G (2002) Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35:843\u2013854","journal-title":"Neuron"},{"key":"66_CR36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1602\/neurorx.2.3.471","volume":"2","author":"DE Merry","year":"2005","unstructured":"Merry DE (2005) Animal models of Kennedy disease. NeuroRx 2:471\u2013479","journal-title":"NeuroRx"},{"key":"66_CR37","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nm878","volume":"9","author":"M Katsuno","year":"2003","unstructured":"Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768\u2013773","journal-title":"Nat Med"},{"key":"66_CR38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00109-004-0530-7","volume":"82","author":"M Katsuno","year":"2004","unstructured":"Katsuno M, Adachi H, Tanaka F, Sobue G (2004) Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives. J Mol Med 82:298\u2013307","journal-title":"J Mol Med"},{"key":"66_CR39","doi-asserted-by":"crossref","unstructured":"Katsuno M, Adachi H, Waza M, Banno H, Suzuki K, Tanaka F, Doyu M, Sobue G (2006) Pathogenesis, animal models and therapeutics in Spinal and bulbar muscular atrophy (SBMA). Exp Neurol (In press)","DOI":"10.1016\/j.expneurol.2006.01.021"},{"key":"66_CR40","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1523\/JNEUROSCI.23-06-02203.2003","volume":"23","author":"H Adachi","year":"2003","unstructured":"Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, Angelidis C, Kusakabe M, Yoshiki A, Kobayashi Y, Doyu M, Sobue G (2003) Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J Neurosci 23:2203\u20132211","journal-title":"J Neurosci"},{"key":"66_CR41","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/hmg\/ddh131","volume":"13","author":"M Minamiyama","year":"2004","unstructured":"Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y, Tanaka F, Doyu M, Inukai A, Sobue G (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13:1183\u20131192","journal-title":"Hum Mol Genet"},{"key":"66_CR42","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20735","volume":"59","author":"H Banno","year":"2006","unstructured":"Banno H, Adachi H, Katsuno M, Suzuki K, Atsuta N, Watanabe H, Tanaka F, Doyu M, Sobue G (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520\u2013526","journal-title":"Ann Neurol"},{"key":"66_CR43","doi-asserted-by":"crossref","first-page":"8007","DOI":"10.1074\/jbc.272.12.8007","volume":"272","author":"W Sullivan","year":"1997","unstructured":"Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Alnemri ES, Litwack G, Toft D (1997) Nucleotides and two functional states of hsp90. J Biol Chem 272:8007\u20138012","journal-title":"J Biol Chem"},{"key":"66_CR44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800000242","volume":"47","author":"MJ Egorin","year":"2001","unstructured":"Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL (2001) Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 47:291\u2013302","journal-title":"Cancer Chemother Pharmacol"},{"key":"66_CR45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2005.03.024","volume":"121","author":"AJ McClellan","year":"2005","unstructured":"McClellan AJ, Scott MD, Frydman J (2005) Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 121:739\u2013748","journal-title":"Cell"},{"key":"66_CR46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1379\/1466-1268(2003)008<0108:PASPWC>2.0.CO;2","volume":"8","author":"SJ Felts","year":"2003","unstructured":"Felts SJ, Toft DO (2003) p23, a simple protein with complex activities. Cell Stress Chaperones 8:108\u2013113","journal-title":"Cell Stress Chaperones"},{"key":"66_CR47","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1074\/jbc.271.37.22796","volume":"271","author":"EG Mimnaugh","year":"1996","unstructured":"Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796\u201322801","journal-title":"J Biol Chem"},{"key":"66_CR48","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-03-3531","volume":"64","author":"P Bonvini","year":"2004","unstructured":"Bonvini P, Dalla Rosa H, Vignes N, Rosolen A (2004) Ubiquitination and proteasomal degradation of nucleophosmin-anaplastic lymphoma kinase induced by 17-allylamino-demethoxygeldanamycin: role of the co-chaperone carboxyl heat shock protein 70-interacting protein. Cancer Res 64:3256\u20133264","journal-title":"Cancer Res"},{"key":"66_CR49","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1128\/MCB.15.12.6804","volume":"15","author":"DF Smith","year":"1995","unstructured":"Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA (1995) Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 15:6804\u20136812","journal-title":"Mol Cell Biol"},{"key":"66_CR50","first-page":"670","volume":"9","author":"JL Johnson","year":"1995","unstructured":"Johnson JL, Toft DO (1995) Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 9:670\u2013678","journal-title":"Mol Endocrinol"},{"key":"66_CR51","first-page":"705","volume":"10","author":"L Whitesell","year":"1996","unstructured":"Whitesell L, Cook P (1996) Stable and specific binding of heat shock protein 90 by geldanamycin disrupts glucocorticoid receptor function in intact cells. Mol Endocrinol 10:705\u2013712","journal-title":"Mol Endocrinol"},{"key":"66_CR52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/1568009033481787","volume":"3","author":"L Whitesell","year":"2003","unstructured":"Whitesell L, Bagatell R, Falsey R (2003) The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 3:349\u2013358","journal-title":"Curr Cancer Drug Targets"},{"key":"66_CR53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.molmed.2004.04.006","volume":"10","author":"A Kamal","year":"2004","unstructured":"Kamal A, Boehm MF, Burrows FJ (2004) Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 10:283\u2013290","journal-title":"Trends Mol Med"},{"key":"66_CR54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrn1587","volume":"6","author":"PJ Muchowski","year":"2005","unstructured":"Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11\u201322","journal-title":"Nat Rev Neurosci"},{"key":"66_CR55","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nm1066","volume":"10","author":"CA Ross","year":"2004","unstructured":"Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10:10\u201317 (Suppl)","journal-title":"Nat Med"},{"key":"66_CR56","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","volume":"431","author":"M Arrasate","year":"2004","unstructured":"Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805\u2013810","journal-title":"Nature"},{"key":"66_CR57","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/hmg\/10.12.1307","volume":"10","author":"A Sittler","year":"2001","unstructured":"Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Hartl MK, Hartl FU, Wanker EE (2001) Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington\u2019s disease. Hum Mol Genet 10:1307\u20131315","journal-title":"Hum Mol Genet"},{"key":"66_CR58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","volume":"10","author":"H Xia","year":"2004","unstructured":"Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816\u2013820","journal-title":"Nat Med"},{"key":"66_CR59","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper SQ, Staber PD, He X, Eliason SL, Martins IH, Mao Q, Yang L, Kotin RM, Paulson HL, Davidson BL (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci U S A 102:5820\u20135825","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR60","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nm1207","volume":"11","author":"C Raoul","year":"2005","unstructured":"Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423\u2013428","journal-title":"Nat Med"},{"key":"66_CR61","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/hmg\/11.5.515","volume":"11","author":"CK Bailey","year":"2002","unstructured":"Bailey CK, Andriola IF, Kampinga HH, Merry DE (2002) Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum Mol Genet 11:515\u2013523","journal-title":"Hum Mol Genet"},{"key":"66_CR62","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nm1005-1052","volume":"11","author":"AR Spada La","year":"2005","unstructured":"La Spada AR, Weydt P (2005) Targeting toxic proteins for turnover. Nat Med 11:1052\u20131053","journal-title":"Nat Med"},{"key":"66_CR63","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/502","volume":"19","author":"CJ Cummings","year":"1998","unstructured":"Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, Zoghbi HY (1998) Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 19:148\u2013154","journal-title":"Nat Genet"},{"key":"66_CR64","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","volume":"40","author":"A Ciechanover","year":"2003","unstructured":"Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40:427\u2013446","journal-title":"Neuron"},{"key":"66_CR65","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.292.5521.1552","volume":"292","author":"NF Bence","year":"2001","unstructured":"Bence NF, Sampat RM, Kopito RR (2001) Impairment of the ubiquitin\u2013proteasome system by protein aggregation. Science 292:1552\u20131555","journal-title":"Science"},{"key":"66_CR66","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/hmg\/10.10.1049","volume":"10","author":"NR Jana","year":"2001","unstructured":"Jana NR, Zemskov EA, Wang G, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10:1049\u20131059","journal-title":"Hum Mol Genet"},{"key":"66_CR67","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/sj.emboj.7600426","volume":"23","author":"CI Holmberg","year":"2004","unstructured":"Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI (2004) Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23:4307\u20134318","journal-title":"EMBO J"},{"key":"66_CR68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1083\/jcb.200306038","volume":"163","author":"H Zhou","year":"2003","unstructured":"Zhou H, Cao F, Wang Z, Yu ZX, Nguyen HP, Evans J, Li SH, Li XJ (2003) Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity. J Cell Biol 163:109\u2013118","journal-title":"J Cell Biol"},{"key":"66_CR69","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/hmg\/ddi064","volume":"14","author":"AB Bowman","year":"2005","unstructured":"Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY (2005) Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin\u2013proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 14:679\u2013691","journal-title":"Hum Mol Genet"},{"key":"66_CR70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/hmg\/ddi423","volume":"15","author":"JS Bett","year":"2006","unstructured":"Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP (2006) Proteasome impairment does not contribute to pathogenesis in R6\/2 Huntington\u2019s disease mice: exclusion of proteasome activator REG{gamma} as a therapeutic target. Hum Mol Genet 15:33\u201344","journal-title":"Hum Mol Genet"},{"key":"66_CR71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 101:57\u201366","journal-title":"Cell"},{"key":"66_CR72","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.2978-04.2004","volume":"24","author":"T Zu","year":"2004","unstructured":"Zu T, Duvick LA, Kaytor MD, Berlinger MS, Zoghbi HY, Clark HB, Orr HT (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 24:8853\u20138861","journal-title":"J Neurosci"},{"key":"66_CR73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0092-8674(03)00349-0","volume":"113","author":"HK Chen","year":"2003","unstructured":"Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, Aitken A, Skoulakis EM, Orr HT, Botas J, Zoghbi HY (2003) Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457\u2013468","journal-title":"Cell"},{"key":"66_CR74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.1115462","volume":"310","author":"V Koprivica","year":"2005","unstructured":"Koprivica V, Cho KS, Park JB, Yiu G, Atwal J, Gore B, Kim JA, Lin E, Tessier-Lavigne M, Chen DF, He Z (2005) EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 310:106\u2013110","journal-title":"Science"},{"key":"66_CR75","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/nm1323","volume":"11","author":"O Herrmann","year":"2005","unstructured":"Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, Malfertheiner M, Kohrmann M, Potrovita I, Maegele I, Beyer C, Burke JR, Hasan MT, Bujard H, Wirth T, Pasparakis M, Schwaninger M (2005) IKK mediates ischemia-induced neuronal death. Nat Med 11:1322\u20131329","journal-title":"Nat Med"},{"key":"66_CR76","first-page":"3312","volume":"6","author":"R Bagatell","year":"2000","unstructured":"Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6:3312\u20133318","journal-title":"Clin Cancer Res"},{"key":"66_CR77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/0014-4827(91)90382-5","volume":"195","author":"Y Murakami","year":"1991","unstructured":"Murakami Y, Uehara Y, Yamamoto C, Fukazawa H, Mizuno S (1991) Induction of hsp 72\/73 by herbimycin A, an inhibitor of transformation by tyrosine kinase oncogenes. Exp Cell Res 195:338\u2013344","journal-title":"Exp Cell Res"},{"key":"66_CR78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0092-8674(00)81588-3","volume":"94","author":"J Zou","year":"1998","unstructured":"Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94:471\u2013480","journal-title":"Cell"},{"key":"66_CR79","first-page":"137","volume":"44","author":"K Rokutan","year":"1998","unstructured":"Rokutan K, Hirakawa T, Teshima S, Nakano Y, Miyoshi M, Kawai T, Konda E, Morinaga H, Nikawa T, Kishi K (1998) Implications of heat shock\/stress proteins for medicine and disease. J Med Investig 44:137\u2013147","journal-title":"J Med Investig"},{"key":"66_CR80","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/70532","volume":"23","author":"JM Warrick","year":"1999","unstructured":"Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, Bonini NM (1999) Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 23:425\u2013428","journal-title":"Nat Genet"},{"key":"66_CR81","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1073\/pnas.97.6.2898","volume":"97","author":"A Wyttenbach","year":"2000","unstructured":"Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington\u2019s disease. Proc Natl Acad Sci U S A 97:2898\u20132903","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR82","doi-asserted-by":"crossref","first-page":"16801","DOI":"10.1073\/pnas.0506249102","volume":"102","author":"M Katsuno","year":"2005","unstructured":"Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 102:16801\u201316806","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR83","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/hmg\/ddh144","volume":"13","author":"DG Hay","year":"2004","unstructured":"Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP (2004) Progressive decrease in chaperone protein levels in a mouse model of Huntington\u2019s disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 13:1389\u20131405","journal-title":"Hum Mol Genet"},{"key":"66_CR84","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1073\/pnas.0500055102","volume":"102","author":"N Agrawal","year":"2005","unstructured":"Agrawal N, Pallos J, Slepko N, Apostol BL, Bodai L, Chang LW, Chiang AS, Thompson LM, Marsh JL (2005) Identification of combinatorial drug regimens for treatment of Huntington\u2019s disease using Drosophila. Proc Natl Acad Sci U S A 102:3777\u20133781","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR85","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1073\/pnas.242720499","volume":"100","author":"F Dou","year":"2003","unstructured":"Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 100:721\u2013726","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR86","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/hmg\/ddh083","volume":"13","author":"L Petrucelli","year":"2004","unstructured":"Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, De Lucia M, McGowan E, Lewis J, Prihar G, Kim J, Dillmann WH, Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM, Wolozin B, Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13:703\u2013714","journal-title":"Hum Mol Genet"},{"key":"66_CR87","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yexcr.2005.04.021","volume":"308","author":"L Benussi","year":"2005","unstructured":"Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, Barbiero L, Binetti G (2005) Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp Cell Res 308:78\u201384","journal-title":"Exp Cell Res"},{"key":"66_CR88","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nm1102-1185","volume":"8","author":"PK Auluck","year":"2002","unstructured":"Auluck PK, Bonini NM (2002) Pharmacological prevention of Parkinson disease in Drosophila. Nat Med 8:1185\u20131186","journal-title":"Nat Med"},{"key":"66_CR89","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1074\/jbc.M412106200","volume":"280","author":"PK Auluck","year":"2005","unstructured":"Auluck PK, Meulener MC, Bonini NM (2005) Mechanisms of suppression of {alpha}-synuclein neurotoxicity by geldanamycin in Drosophila. J Biol Chem 280:2873\u20132878","journal-title":"J Biol Chem"},{"key":"66_CR90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jmb.2005.06.060","volume":"351","author":"TR Flower","year":"2005","unstructured":"Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN (2005) Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson\u2019s disease. J Mol Biol 351:1081\u20131100","journal-title":"J Mol Biol"},{"key":"66_CR91","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1471-4159.2002.00835.x","volume":"81","author":"A Lu","year":"2002","unstructured":"Lu A, Ran R, Parmentier-Batteur S, Nee A, Sharp FR (2002) Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J Neurochem 81:355\u2013364","journal-title":"J Neurochem"},{"key":"66_CR92","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1242\/jeb.01034","volume":"207","author":"RG Giffard","year":"2004","unstructured":"Giffard RG, Xu L, Zhao H, Carrico W, Ouyang Y, Qiao Y, Sapolsky R, Steinberg G, Hu B, Yenari MA (2004) Chaperones, protein aggregation, and brain protection from hypoxic\/ischemic injury. J Exp Biol 207:3213\u20133220","journal-title":"J Exp Biol"},{"key":"66_CR93","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jnr.10139","volume":"67","author":"P Murphy","year":"2002","unstructured":"Murphy P, Sharp A, Shin J, Gavrilyuk V, Dello Russo C, Weinberg G, Sharp FR, Lu A, Heneka MT, Feinstein DL (2002) Suppressive effects of ansamycins on inducible nitric oxide synthase expression and the development of experimental autoimmune encephalomyelitis. J Neurosci Res 67:461\u2013470","journal-title":"J Neurosci Res"},{"key":"66_CR94","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1471-4159.1999.0720095.x","volume":"72","author":"N Xiao","year":"1999","unstructured":"Xiao N, Callaway CW, Lipinski CA, Hicks SD, DeFranco DB (1999) Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line. J Neurochem 72:95\u2013101","journal-title":"J Neurochem"},{"key":"66_CR95","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0028-3908(01)00018-1","volume":"40","author":"M Sano","year":"2001","unstructured":"Sano M (2001) Radicicol and geldanamycin prevent neurotoxic effects of anti-cancer drugs on cultured embryonic sensory neurons. Neuropharmacology 40:947\u2013953","journal-title":"Neuropharmacology"},{"key":"66_CR96","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1179\/016164103101202183","volume":"25","author":"L Xu","year":"2003","unstructured":"Xu L, Ouyang YB, Giffard RG (2003) Geldanamycin reduces necrotic and apoptotic injury due to oxygen-glucose deprivation in astrocytes. Neurol Res 25:697\u2013700","journal-title":"Neurol Res"},{"key":"66_CR97","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neulet.2005.01.055","volume":"380","author":"YB Ouyang","year":"2005","unstructured":"Ouyang YB, Xu L, Giffard RG (2005) Geldanamycin treatment reduces delayed CA1 damage in mouse hippocampal organotypic cultures subjected to oxygen glucose deprivation. Neurosci Lett 380:229\u2013233","journal-title":"Neurosci Lett"},{"key":"66_CR98","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1745-7270.2005.00069.x","volume":"37","author":"F Dou","year":"2005","unstructured":"Dou F, Yuan LD, Zhu JJ (2005) Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim Biophys Sin (Shanghai) 37:501\u2013505","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"66_CR99","doi-asserted-by":"crossref","first-page":"21711","DOI":"10.1016\/S0021-9258(20)80600-0","volume":"268","author":"LF Stancato","year":"1993","unstructured":"Stancato LF, Chow YH, Hutchison KA, Perdew GH, Jove R, Pratt WB (1993) Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem 268:21711\u201321716","journal-title":"J Biol Chem"},{"key":"66_CR100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1750-3639.2001.tb00387.x","volume":"11","author":"I Ferrer","year":"2001","unstructured":"Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Vinals F, Ribalta T (2001) Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11:144\u2013158","journal-title":"Brain Pathol"},{"key":"66_CR101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0169-328X(02)00488-6","volume":"109","author":"JJ Pei","year":"2002","unstructured":"Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K, Grundke-Iqbal I (2002) Up-regulation of mitogen-activated protein kinases ERK1\/2 and MEK1\/2 is associated with the progression of neurofibrillary degeneration in Alzheimer\u2019s disease. Brain Res Mol Brain Res 109:45\u201355","journal-title":"Brain Res Mol Brain Res"},{"key":"66_CR102","doi-asserted-by":"crossref","first-page":"34918","DOI":"10.1074\/jbc.M302841200","volume":"278","author":"MA Fevre-Bernt La","year":"2003","unstructured":"LaFevre-Bernt MA, Ellerby LM (2003) Kennedy\u2019s disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death. J Biol Chem 278:34918\u201334924","journal-title":"J Biol Chem"},{"key":"66_CR103","doi-asserted-by":"crossref","first-page":"11975","DOI":"10.1073\/pnas.95.20.11975","volume":"95","author":"B Murray","year":"1998","unstructured":"Murray B, Alessandrini A, Cole AJ, Yee AG, Furshpan EJ (1998) Inhibition of the p44\/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc Natl Acad Sci U S A 95:11975\u201311980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR104","doi-asserted-by":"crossref","first-page":"E45","DOI":"10.1126\/stke.2512004pe45","volume":"2004","author":"EC Cheung","year":"2004","unstructured":"Cheung EC, Slack RS (2004) Emerging role for ERK as a key regulator of neuronal apoptosis. Sci STKE 2004:PE45","journal-title":"Sci STKE"},{"key":"66_CR105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1083\/jcb.200403028","volume":"165","author":"S Subramaniam","year":"2004","unstructured":"Subramaniam S, Zirrgiebel U, von Bohlen Und Halbach O, Strelau J, Laliberte C, Kaplan DR, Unsicker K (2004) ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165:357\u2013369","journal-title":"J Cell Biol"},{"key":"66_CR106","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000067426","volume":"11","author":"X Zhu","year":"2002","unstructured":"Zhu X, Lee HG, Raina AK, Perry G, Smith MA (2002) The role of mitogen-activated protein kinase pathways in Alzheimer\u2019s disease. NeuroSignals 11:270\u2013281","journal-title":"NeuroSignals"},{"key":"66_CR107","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/hmg\/ddi122","volume":"14","author":"MD Kaytor","year":"2005","unstructured":"Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, Orr HT (2005) A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet 14:1095\u20131105","journal-title":"Hum Mol Genet"},{"key":"66_CR108","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1073\/pnas.170276797","volume":"97","author":"S Sato","year":"2000","unstructured":"Sato S, Fujita N, Tsuruo T (2000) Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A 97:10832\u201310837","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR109","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1158\/0008-5472.CAN-04-0006","volume":"64","author":"P George","year":"2004","unstructured":"George P, Bali P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Fiskus W, Scuto A, Annavarapu S, Moscinski L, Bhalla K (2004) Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64:3645\u20133652","journal-title":"Cancer Res"},{"key":"66_CR110","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","volume":"13","author":"SR Datta","year":"1999","unstructured":"Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13:2905\u20132927","journal-title":"Genes Dev"},{"key":"66_CR111","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.0022-3042.2001.00761.x","volume":"80","author":"KS Pai","year":"2002","unstructured":"Pai KS, Cunningham DD (2002) Geldanamycin specifically modulates thrombin-mediated morphological changes in mouse neuroblasts. J Neurochem 80:715\u2013718","journal-title":"J Neurochem"},{"key":"66_CR112","doi-asserted-by":"crossref","first-page":"12847","DOI":"10.1073\/pnas.202365899","volume":"99","author":"W Xu","year":"2002","unstructured":"Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2\/Neu. Proc Natl Acad Sci U S A 99:12847\u201312852","journal-title":"Proc Natl Acad Sci U S A"},{"key":"66_CR113","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1074\/jbc.M209494200","volume":"278","author":"SJ Lavictoire","year":"2003","unstructured":"Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, Lorimer IA (2003) Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278:5292\u20135299","journal-title":"J Biol Chem"},{"key":"66_CR114","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1097-2765(02)00450-1","volume":"9","author":"G Chen","year":"2002","unstructured":"Chen G, Cao P, Goeddel DV (2002) TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9:401\u2013410","journal-title":"Mol Cell"},{"key":"66_CR115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1172\/JCI23493","volume":"115","author":"T Luedde","year":"2005","unstructured":"Luedde T, Assmus U, Wustefeld T, Meyer zu Vilsendorf A, Roskams T, Schmidt-Supprian M, Rajewsky K, Brenner DA, Manns MP, Pasparakis M, Trautwein C (2005) Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia\/reperfusion injury. J Clin Invest 115:849\u2013859","journal-title":"J Clin Invest"},{"key":"66_CR116","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/hmg\/ddi443","volume":"15","author":"BL Apostol","year":"2006","unstructured":"Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1\/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15:273\u2013285","journal-title":"Hum Mol Genet"},{"key":"66_CR117","doi-asserted-by":"crossref","first-page":"6703","DOI":"10.1074\/jbc.M110338200","volume":"277","author":"C Song","year":"2002","unstructured":"Song C, Perides G, Liu YF (2002) Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 277:6703\u20136707","journal-title":"J Biol Chem"},{"key":"66_CR118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/hmg\/ddi067","volume":"14","author":"JC Lievens","year":"2005","unstructured":"Lievens JC, Rival T, Iche M, Chneiweiss H, Birman S (2005) Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 14:713\u2013724","journal-title":"Hum Mol Genet"},{"key":"66_CR119","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1056\/NEJMe058227","volume":"353","author":"Y Levy","year":"2005","unstructured":"Levy Y, Gorshtein A (2005) Chaperones and disease. N Engl J Med 353:2821\u20132822","journal-title":"N Engl J Med"},{"key":"66_CR120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0065-3233(01)59005-1","volume":"59","author":"LH Pearl","year":"2001","unstructured":"Pearl LH, Prodromou C (2001) Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem 59:157\u2013186","journal-title":"Adv Protein Chem"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-006-0066-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00109-006-0066-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-006-0066-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T15:50:45Z","timestamp":1683474645000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00109-006-0066-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,2]]},"references-count":120,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s00109-006-0066-0","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,2]]}}}